Skip to content
Inciteful Med

Looking Ahead: Monitoring and Family Screening

Last updated:

Long-term care for ATTRv V30M amyloidosis requires regular neurological exams, cardiac imaging, and biomarker tracking to ensure the disease is stable. Because it is an inherited condition, first-degree relatives should undergo genetic counseling and cascade screening to identify risk early.

Key Takeaways

  • • Regular monitoring with mNIS+7 exams, cardiac imaging, and biomarker tests helps ensure your amyloidosis treatment is working.
  • • Because ATTRv V30M is an inherited condition, first-degree relatives should consider genetic counseling and cascade screening.
  • • Family members who carry the mutation but have no symptoms should be closely monitored to catch the earliest signs of the disease.
  • • Routine eye exams are critical because amyloid deposits can affect the eyes, even when you are actively on treatment.
  • • Managing daily symptoms like neuropathic pain, digestive issues, and dizziness is a vital part of maintaining your quality of life.

Living with ATTRv V30M Amyloidosis is a long-term journey that requires a proactive approach to monitoring both your own health and the health of your family. Because this is a progressive condition, the goal of “survivorship” is to catch any changes early so that your treatment can be adjusted to keep you as healthy as possible [1][2].

Your Monitoring Schedule

Once you are on a treatment plan, your care team will use several “measuring sticks” to ensure the disease is being held in check.

  • Neurological Monitoring: You will likely have a specialized exam called an mNIS+7 (modified Neuropathy Impairment Score) every 6 to 12 months [3][4]. This test measures your strength, reflexes, and sensation to see if your neuropathy is stable [4].
  • Biomarker Tracking: Regular blood tests for sNfL (a marker of nerve damage) and NT-proBNP (a marker of heart stress) are essential [5][6]. Rising levels can be an “early warning system” that the disease is becoming more active [7][8].
  • Cardiac Imaging: Even if your primary symptoms are neurological, you will likely have an echocardiogram or cardiac MRI annually to ensure your heart remains healthy [9][10].
  • Routine Eye Exams: The V30M mutation is known to cause amyloid deposits in the eyes, leading to conditions like “vitreous opacities” or glaucoma [11][12]. Since many silencer therapies do not cross effectively into the eye, routine checkups with an ophthalmologist remain critical even while on treatment [13].

Protecting Your Family: Cascade Screening

ATTRv V30M is an autosomal dominant condition, which means there is a 50% chance that any child or sibling of a person with the mutation also carries it [10].

  • Genetic Counseling: This is the first step for your relatives. A genetic counselor can help them understand the risks and benefits of testing [14][15].
  • Cascade Screening: This is the process of testing first-degree relatives (parents, siblings, and adult children) to identify who else may be at risk [16][17]. Identifying a carrier before they have symptoms is the most powerful way to prevent future damage [18][19].

Monitoring Asymptomatic Carriers

If a family member tests positive for the mutation but has no symptoms, they are considered an asymptomatic carrier. They are not simply “watched and waited”—they are actively monitored to catch the very first signs of the disease (called “phenoconversion”) [20][21].

  • Sudoscan: A quick, non-invasive test that measures sweat gland function, which is often one of the first things to change when small nerves are affected [22][23].
  • sNfL Blood Tests: Levels of this protein can start to rise even a year before a patient feels their first symptom [7][5].
  • Skin Biopsy: A tiny sample of skin can be checked for reduced nerve fiber density (IENFD), a sign that the disease is beginning to affect the small nerves [24][25].

Daily Management & Quality of Life

Managing the “invisible” symptoms of V30M is a key part of daily life.

  • Orthostatic Hypotension (Dizziness): To manage dizziness when standing, your doctor may recommend non-drug strategies like wearing compression stockings or increasing salt and fluid intake [26]. If these aren’t enough, medications like droxidopa may be prescribed [26].
  • Gastrointestinal (GI) Support: Issues like diarrhea or constipation are common and should be addressed early with your gastroenterologist to prevent weight loss and maintain your energy levels [27][28].
  • Neuropathic Pain: Nearly 70% of patients experience nerve pain [29]. Working with a pain specialist or neurologist to find the right balance of medication is essential for maintaining your daily activities and quality of life [29].

Frequently Asked Questions

How often do I need a neurological exam for ATTRv V30M amyloidosis?
You will typically have a specialized neurological exam called an mNIS+7 every 6 to 12 months. This test measures your strength, reflexes, and sensation to ensure your neuropathy is remaining stable on your current treatment plan.
Should my family members be tested for the V30M mutation?
Because ATTRv V30M is an inherited condition, first-degree relatives like parents, siblings, and children have a 50% chance of carrying the mutation. A genetic counselor can help your family members understand the benefits of cascade screening to identify carriers before symptoms begin.
How are asymptomatic carriers of the V30M mutation monitored?
Relatives who carry the mutation but feel fine are actively monitored to catch the very first signs of the disease. This monitoring often includes sweat gland tests like Sudoscan, sNfL blood tests, and skin biopsies to check for early small nerve damage.
Why do I need routine eye exams if my symptoms are mainly neurological?
The V30M mutation can cause amyloid proteins to build up in the eyes, potentially leading to issues like vitreous opacities or glaucoma. Since many systemic treatments do not effectively cross into the eye, routine checkups with an ophthalmologist remain critical.
How can I manage dizziness and orthostatic hypotension?
Your doctor may first recommend non-drug strategies such as wearing compression stockings or increasing your daily salt and fluid intake. If you still experience dizziness when standing, they may prescribe medications like droxidopa to help manage your blood pressure.

Questions for Your Doctor

  • • What is our specific schedule for re-testing my sNfL levels and NT-proBNP markers?
  • • How often should I have an mNIS+7 neurological exam to ensure my treatment is effectively stabilizing my nerves?
  • • Can you provide me with a 'family letter' that I can share with my siblings and children to help them start the genetic counseling process?
  • • For my relatives who test positive as carriers but don't have symptoms yet, what is your protocol for their monitoring (e.g., Sudoscan, skin biopsy, or sNfL)?
  • • Which non-drug strategies do you recommend for managing my orthostatic hypotension (dizziness when standing) and GI symptoms?

Questions for You

  • • How are you feeling emotionally about sharing your diagnosis with your family members, and do you have the support you need for those conversations?
  • • Have you noticed small changes in your daily life, like feeling fuller faster after eating, or needing to be more careful when standing up quickly?
  • • Are you keeping a log of your neuropathic pain—where it is, what it feels like, and what time of day it is worst—to share with your doctor?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience.

    Suhr OB, Gustavsson S, Heldestad V, et al.

    Degenerative neurological and neuromuscular disease 2012; (2()):93-106 doi:10.2147/DNND.S24652.

    PMID: 30890882
  2. 2

    Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report.

    Miyazaki Y

    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 2017; (54(1)):75-80 doi:10.3143/geriatrics.54.75.

    PMID: 28202889
  3. 3

    Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

    Benson MD, Waddington-Cruz M, Berk JL, et al.

    The New England journal of medicine 2018; (379(1)):22-31 doi:10.1056/NEJMoa1716793.

    PMID: 29972757
  4. 4

    Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.

    Dyck PJB, González-Duarte A, Obici L, et al.

    Journal of the neurological sciences 2019; (405()):116424 doi:10.1016/j.jns.2019.116424.

    PMID: 31445300
  5. 5

    Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Hereditary Transthyretin Amyloidosis Polyneuropathy.

    Loser V, Benkert P, Vicino A, et al.

    Journal of the peripheral nervous system : JPNS 2026; (31(1)):e70104 doi:10.1111/jns.70104.

    PMID: 41640232
  6. 6

    Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.

    Ingebrigtsen A, Saeed S, Larsen TH, Reikvam H

    Scandinavian journal of clinical and laboratory investigation 2024; (84(3)):193-201 doi:10.1080/00365513.2024.2346908.

    PMID: 38709651
  7. 7

    Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.

    Berends M, Brunger AF, Bijzet J, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2024; (31(2)):132-141 doi:10.1080/13506129.2024.2327342.

    PMID: 38477065
  8. 8

    Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).

    Kristen AV, Maurer MS, Rapezzi C, et al.

    PloS one 2017; (12(4)):e0173086 doi:10.1371/journal.pone.0173086.

    PMID: 28384285
  9. 9

    Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation.

    Björkenheim A, Szabó B, Sztaniszláv ÁJ

    BMJ case reports 2020; (13(1)) doi:10.1136/bcr-2019-232756.

    PMID: 31932463
  10. 10

    Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area.

    Wang S, Sun J, Lu Q, et al.

    International medical case reports journal 2022; (15()):299-306 doi:10.2147/IMCRJ.S357236.

    PMID: 35734096
  11. 11

    PARS PLANA VITRECTOMY FOR THE TREATMENT OF VITREOUS AMYLOID IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS.

    Marques JH, Morais I, Coelho J, et al.

    Retina (Philadelphia, Pa.) 2024; (44(12)):2098-2104 doi:10.1097/IAE.0000000000004243.

    PMID: 39121491
  12. 12

    Elderly onset vitreous opacities as the initial manifestation in hereditary transthyretin (ATTR Val30Met) carries.

    Ishida K, Nishida T, Niimi Y, et al.

    Ophthalmic genetics 2017; (38(4)):387-391 doi:10.1080/13816810.2016.1232413.

    PMID: 28085522
  13. 13

    OCULAR ANGIOGRAPHIC FEATURES IN JAPANESE PATIENTS WITH VAL30MET HEREDITARY TRANSTHYRETIN AMYLOIDOSIS.

    Kakihara S, Hirano T, Kitahara J, et al.

    Retina (Philadelphia, Pa.) 2022; (42(1)):210-215 doi:10.1097/IAE.0000000000003291.

    PMID: 34483312
  14. 14

    Subjects at Risk for Genetic Late-Onset Neurological Diseases: Objective Knowledge.

    Leite Â, Leite F, Dinis MAP

    Public health genomics 2017; (20(3)):158-165 doi:10.1159/000479292.

    PMID: 28813711
  15. 15

    Long-term predictors for psychological outcome of pre-symptomatic testing for late-onset neurological diseases.

    Lêdo S, Ramires A, Leite Â, et al.

    European journal of medical genetics 2018; (61(10)):575-580 doi:10.1016/j.ejmg.2018.03.010.

    PMID: 29581083
  16. 16

    The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.

    Lavigne-Moreira C, Marques VD, Gonçalves MVM, et al.

    Journal of the peripheral nervous system : JPNS 2018; (23(2)):134-137 doi:10.1111/jns.12259.

    PMID: 29520877
  17. 17

    Twenty Years of a Pre-Symptomatic Testing Protocol for Late-Onset Neurological Diseases in Portugal.

    Paneque M, Félix J, Mendes Á, et al.

    Acta medica portuguesa 2019; (32(4)):295-304 doi:10.20344/amp.10526.

    PMID: 31067424
  18. 18

    Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.

    Martens B, De Pauw M, De Bleecker JL

    Acta neurologica Belgica 2018; (118(2)):179-185 doi:10.1007/s13760-018-0906-z.

    PMID: 29524093
  19. 19

    Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.

    Ando Y, Waddington-Cruz M, Sekijima Y, et al.

    Orphanet journal of rare diseases 2023; (18(1)):323 doi:10.1186/s13023-023-02910-3.

    PMID: 37828588
  20. 20

    Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.

    Beauvais D, Labeyrie C, Cauquil C, et al.

    Journal of neurology, neurosurgery, and psychiatry 2024; (95(6)):489-499 doi:10.1136/jnnp-2023-332180.

    PMID: 37875336
  21. 21

    Early cardiac sympathetic denervation in hereditary transthyretin amyloidosis: 123I-metaiodobenzylguanidine findings and correlation with skin biopsy.

    Frantellizzi V, Cambieri C, Galosi E, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026; 1-13 doi:10.1080/13506129.2026.2636657.

    PMID: 41773910
  22. 22

    Correlation between a commercial electrophysiological test of sudomotor function and intraepidermal nerve fiber density in hereditary transthyretin amyloidosis.

    Masuda T, Misumi Y, Nomura T, et al.

    Muscle & nerve 2024; (69(1)):99-102 doi:10.1002/mus.28005.

    PMID: 37960924
  23. 23

    Hereditary transthyretin-related amyloidosis.

    Finsterer J, Iglseder S, Wanschitz J, et al.

    Acta neurologica Scandinavica 2019; (139(2)):92-105 doi:10.1111/ane.13035.

    PMID: 30295933
  24. 24

    Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.

    Leonardi L, Adam C, Beaudonnet G, et al.

    European journal of neurology 2022; (29(5)):1477-1487 doi:10.1111/ene.15268.

    PMID: 35100482
  25. 25

    Intracutaneous Amyloid Deposition is Associated With Nerve Conduction Studies Deterioration in Presumed Asymptomatic Pathogenic Variant TTR Carriers.

    Schulz N, Beauvais D, Cauquil C, et al.

    European journal of neurology 2025; (32(7)):e70277 doi:10.1111/ene.70277.

    PMID: 40653952
  26. 26

    Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.

    Palma JA, Gonzalez-Duarte A, Kaufmann H

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):33-44 doi:10.1007/s10286-019-00623-x.

    PMID: 31452021
  27. 27

    Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.

    Obici L, Suhr OB

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):55-63 doi:10.1007/s10286-019-00628-6.

    PMID: 31452022
  28. 28

    Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.

    Gendre T, Planté-Bordeneuve V

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):25-31 doi:10.1007/s10286-019-00624-w.

    PMID: 31506870
  29. 29

    Neuropathic pain experience in symptomatic and presymptomatic subjects carrying a transthyretin gene mutation.

    Tozza S, Luigetti M, Antonini G, et al.

    Frontiers in neurology 2023; (14()):1109782 doi:10.3389/fneur.2023.1109782.

    PMID: 36846120

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or genetic counselor about monitoring and family screening for ATTRv V30M amyloidosis.

Stay up to date

Get notified when new research about ATTRV30M amyloidosis is published.

No spam. Unsubscribe anytime.